microbeПроблемы особо опасных инфекцийProblems of Particularly Dangerous Infections0370-10692658-719XRussian Research Anti-Plague Institute “Microbe”10.21055/0370-1069-2013-3-63-69microbe-63Research ArticleИММУНОЛОГИЯ, ПРОФИЛАКТИКАIMMUNOLOGY, PROPHYLAXISИсторические и современные представления о проблеме специфической профилактики чумыHistorical and Modern Views on the Problem of Specific Plague ProphylaxisБугорковаС. А.BugorkovaS. A.rusrapi@microbe.ruДевдарианиЗ. Л.DevdarianiZ. L.rusrapi@microbe.ruЩуковскаяТ. Н.ShchukovskayaT. N.rusrapi@microbe.ruКутыревВ. В.KutyrevV. V.rusrapi@microbe.ruРоссийский научно-исследовательский противочумный институт «Микроб»РоссияRussian Research Anti-Plague Institute “Microbe”Russian Federation201320092013036369Copyright © Бугоркова С.А., Девдариани З.Л., Щуковская Т.Н., Кутырев В.В., 20132013Бугоркова С.А., Девдариани З.Л., Щуковская Т.Н., Кутырев В.В.Bugorkova S.A., Devdariani Z.L., Shchukovskaya T.N., Kutyrev V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.microbe.ru/jour/article/view/63

Целью данного обзора был анализ, проведенный в историческом аспекте, изменений представлений о проблеме специфической профилактики чумы и оценка вклада современных достижений научных исследований в области изучения возбудителя чумы и особенностей его взаимодействия с организмом хозяина в решение ключевой задачи разработки эффективных и безопасных вакцин для борьбы с этой грозной болезнью. Рассмотрены исторические вопросы становления представлений о специфической профилактике чумы, связанные с выдающимися научными открытиями французского ученого-микробиолога А.Иерсина. Приведены сведения по современному состоянию иммунопрофилактики чумы в мире и России. Через призму проводимых научных исследований с применением достижений передовых технологий медицинской науки (молекулярной биологии, биотехнологии, биоинформатики, молекулярной иммунологии) представлены перспективы поиска и разработки эффективных и безопасных противочумных вакцин нового поколения.

Objective of this review is to analyze diachronically paradigm shift as regards problems of specific plague prophylaxis and appreciate contribution of the present-day scientific discoveries in the sphere of plague agent investigations and peculiarities of its interaction with host organism to the solution of topical issues of vaccine development that will be safe and tangibly effective against this particularly dangerous disease. Outlined is the historical background of the conceptual evolution concerning specific plague prophylaxis and events that are landmarked with eminent scientific discoveries by A.Yersin, French researcher and microbiologist. Given are the data on the current state of plague immune-prophylaxis both in Russia and around the world. Through the prism of the latest researches that assume application of advanced technological resource of medical sciences (molecular biology, biotechnology, bioinformatics, molecular immunology) put forward is the prospective of search and construction of safe and effective anti-plague next generation vaccines.

чумаиммунопрофилактикавакциныplagueimmune-prophylaxisvaccinesReferencesБывалов А.А., Евстигнеев В.И., Дармов И.В., Пименов Е.М. Антигенный состав чумной химической вакцины. Патент РФ 2190424, опубл. 10.10.2002.Byvalov A.A., Evstigneev V.I., Darmov I.V., Pimenov E.M. [Antigen composition of plague chemical vaccine]. RF Patent 2190424.Ганин В. Война с «черной смертью»: от обороны к наступлению. Наука и жизнь. 2006; 7:17–24.Ganin V. [The war on “black death”: change from defense to offense]. Nauka i zhizn’. 2006; 7:17–24.Дальвадянц С.М., Дубровин М.Ю., Бывалов А.А., Додонов Н.П., Чичерин Ю.В., Евстигнеев В.И., Пименов Е.В., Еремин С.А., Дятлов И.А., Кутырев В.В. Исследования по иммунизации против чумы. Сообщение 3. Ревакцинирующие свойства живой чумной вакцины и препаратов чумных химических вакцин для павианов гамадрилов. Пробл. особо опасных инф. 2005; 1(89):62–7.Dalvadyants S.M., Dubrovin M.Yu., Byvalov A.A., Dodonov N.P., Chicherin Yu.V., Evstigneev V.I., Pimenov E.V., Yeremin S.A, Dyatlov I.A, Kutyrev V.V. [A study of immunization against plague. Communication 3. Revaccination properties of the plague vaccine and the preparations of plague chemical vaccines for Hamadryas baboons]. Probl. Osobo Opasn. Infek. 2005; 89:62–7.Дальвадянц С.М., Дятлов И.А., Еремин С.А., Щуковская Т.Н., Саяпина Л.В., Сергеева Г.М., Кутырев В.В. Исследования по иммунизации против чумы. Сообщение 4. Опыт ревакцинации волонтеров «химической» и живой чумной вакцинами. Пробл. особо опасных инф. 2006; 1(91):57–61.Dalvadyants S.M., Dyatlov I.A., Yeremin S.A., Schukovskaya T.N., Sayapina L.V., Sergheyeva G.M., Kutyrev V.V. [Plague immunization studies. Communication 4. An experience of volunteer revaccination with the “chemical” and live plague vaccines]. Probl. Osobo Opasn. Infek. 2006; 91:57–61.Дармов И.В., Погорельский И.П., Ежов А.В., Мохов Д.А., Хонин А.З. Изучение иммунобиологических свойств вакцины чумной живой сухой на основе штамма ЕВ Р2 Y. pestis. В кн.: Научные труды, посвященные 75-летию НИИ микробиологии МО РФ. Киров; 2003. С. 77.Darmov I.V., Pogorel’sky I.P., Ezhov A.V., Mokhov D.A., Khonin A.Z. [Studies of immunobiological properties of a EV P2 Y. pestis-based dry live plague vaccine]. In: [Scientific Works Devoted to the 75th Anniversary of the Research Institute of Microbiology of the RF Ministry of Defense]. Kirov; 2003. P. 77.Евстигнеев В.И., Абдуллин Т.Г. Вклад НИИ микробиологии МО РФ в становлении системы биологической защиты войск и населения России. В кн.: Диагностика, лечение и профилактика опасных инфекционных заболеваний. Биотехнология. Ветеринария. Киров, 1998. С. 3–10.Evstigneev V.I., Abdullin T.G. [Contribution of the Research Institute of Microbiology (the RF Ministry of Defense) to the development of the system providing for biological protection of RF military forces and population]. In: [Diagnostics, Treatment, and Prophylaxis of Infectious Diseases. Biotechnology. Veterinary]. Kirov, 1988. P. 3–10.Коробкова Е.И. Живая противочумная вакцина. М.: Медгиз; 1956. 206 с.Korobkova E.I. [Live Anti-Plague Vaccine]. M.: Medgiz; 1956. 206 p.Кутырев В.В., Ерошенко Г.А., Куклева Л.М., Шавина Н.Ю., Виноградова Н.А. Сравнительная генетическая характеристика вакцинного штаммма Yersinia pestis EV и его предполагаемых «вирулентных производных». Журн. микробиол., эпидемиол. и иммунобиол. 2009; 3:50–6Kutyrev V.V., Eroshenko G.A., Kukleva L.M., Shavina N.Yu., Vinogradova N.A. [Comparative genetic characteristics of the vaccine strain Yersinia pestis EV and its proposed ”virulent derivates”]. Zh. Mikrobiol. Epidemiol. Immunobiol. 2009; 3:50–6.Лебедев К.А., Понякина И.Д. Иммунология образраспознающих рецепторов (Интегральная иммунология). М: «ЛИБРОКОМ»; 2009. 256 с.Lebedev K.A., Ponyakina I.D. [Immunology of Pattern Recognition Receptor (Integral Immunology)]. M.: “LIBROKOM”; 2009. 256 p.Супотницкий М.В., Супотницкая Н.С. Очерки истории чумы. М.: Вузовская книга; 2006. Кн. 1. 468 с.Supotnitsky M.V., Supotnitskaya N.S. [Notes on the History of Plague]. M.: Vuzovskaya kniga; 2006. Vol. 1.468 p.Airhart C.L., Rohde H.N., Hovde C.J., Bohach G.A., Deobald C.F., Lee S.S., Minnich S.A. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine. Vaccine. 2008; 26:5554–61.Airhart C.L., Rohde H.N., Hovde C.J., Bohach G.A., Deobald C.F., Lee S.S., Minnich S.A. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine. Vaccine. 2008; 26:5554–61.Albrecht M.T., Eyles J.E., Baillie L.W., Keane-Myers A.M. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model. FEMS Immunology & Medical Microbiology. 2012; 65(3):505–9.Albrecht M.T., Eyles J.E., Baillie L.W., Keane-Myers A.M. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model. FEMS Immunology & Medical Microbiology. 2012; 65(3):505–9.Amedei A., Niccolai E., Marino L., D’Elios M. Role of immune response in Yersinia pestis infection. J. Infect. Dev. Ctries. 2011; 5(9):628–39.Amedei A., Niccolai E., Marino L., D’Elios M. Role of immune response in Yersinia pestis infection. J. Infect. Dev. Ctries. 2011; 5(9):628–39.Blisnick T., Ave P., Huerre M., Carniel E., Demeure C.E. Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect. Immun. 2008; 76(8):3808–16Blisnick T., Ave P., Huerre M., Carniel E., Demeure C.E. Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect. Immun. 2008; 76(8):3808–16Boyer J.L., Sofer-Podesta C., Ang J., Hackett N.R., Chiuchiolo M.J., Senina S., Perlin D., Crystal R.G. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum Gene Ther. 2010; 21(7):891–901.Boyer J.L., Sofer-Podesta C., Ang J., Hackett N.R., Chiuchiolo M.J., Senina S., Perlin D., Crystal R.G. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum Gene Ther. 2010; 21(7):891–901.Branger C.G., Sun W., Torres-Escobar A., Perry R., Roland K.L., Fetherston J., Curtiss R., III. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge. Vaccine. 2010; 29:274–82.Branger C.G., Sun W., Torres-Escobar A., Perry R., Roland K.L., Fetherston J., Curtiss R., III. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge. Vaccine. 2010; 29:274–82.Caulfield A.J., Lathem W.W. Substrates of the plasminogen activator protease of Yersinia pestis. Adv. Exp. Med. Biol. 2012; 954:253–60.Caulfield A.J., Lathem W.W. Substrates of the plasminogen activator protease of Yersinia pestis. Adv. Exp. Med. Biol. 2012; 954:253–60.Cooper A.M., Khader S. IL-12p40: an inherently agonistic cytokine. Trends Immunol. 2007; 28:33–8.Cooper A.M., Khader S. IL-12p40: an inherently agonistic cytokine. Trends Immunol. 2007; 28:33–8.Covert B.A., Spencer J.S., Orme I.M., Belisle J.T. The application of proteomics in defining the T-cell antigens of Mycobacterium tuberculosis. Proteomic. 2001; 1(4):574–86.Covert B.A., Spencer J.S., Orme I.M., Belisle J.T. The application of proteomics in defining the T-cell antigens of Mycobacterium tuberculosis. Proteomic. 2001; 1(4):574–86.Cowan C., Jones H.A., Kaya Y.H., Perry R.D., Straley S.C. Invasion of epithelial cells by Yersinia pestis: evidence for a Y. pestis-specific invasin. Infect Immun. 2000; 68(8):4523–30.Cowan C., Jones H.A., Kaya Y.H., Perry R.D., Straley S.C. Invasion of epithelial cells by Yersinia pestis: evidence for a Y. pestis-specific invasin. Infect Immun. 2000; 68(8):4523–30.Dabbagh K., Dahl M.E., Stepick-Biek P., Lewis D.B. Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J. Immunol. 2002; 168:4524–7.Dabbagh K., Dahl M.E., Stepick-Biek P., Lewis D.B. Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J. Immunol. 2002; 168:4524–7.Dziarski R. Innate immunity. Shaechter’s Mechanisms of Microbial Disease. 4th ed. Engelberg R., DiRita V., editors. Lippincott: Williams & Wilkins; 2006. P. 66–89.Dziarski R. Innate immunity. Shaechter’s Mechanisms of Microbial Disease. 4th ed. Engelberg R., DiRita V., editors. Lippincott: Williams & Wilkins; 2006. P. 66–89.Eisenbarth S.C., Piggott D.A., Huleatt J.W., Visintin I., Herrick C.A., Bottomly K. Lipopolysaccharide-enhanced Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J. Exp. Med. 2002; 196:1645–51.Eisenbarth S.C., Piggott D.A., Huleatt J.W., Visintin I., Herrick C.A., Bottomly K. Lipopolysaccharide‐enhanced Toll‐like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J. Exp. Med. 2002; 196:1645–51.Erova T.E., Rosenzweig J.A., Sha J., Suarez G., Sierra J.C., Kirtley M.L., van Lier C.S., Telepnev M.V., Motin V.L., Chopra A.K. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague accine. Clin. Vaccine Immunol. 2013; 20(2):227–38.Erova T.E., Rosenzweig J.A., Sha J., Suarez G., Sierra J.C., Kirtley M.L., van Lier C.S., Telepnev M.V., Motin V.L., Chopra A.K. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague accine. Clin. Vaccine Immunol. 2013; 20(2):227–38.Gelman A.E., Zhang J., Choi Y., Turka L.A. Toll-like receptor ligands directly promote activated CD4 T cell survival. J. Immunol. 2004; 172:6065–73.Gelman A.E., Zhang J., Choi Y., Turka L.A. Toll-like receptor ligands directly promote activated CD4 T cell survival. J. Immunol. 2004; 172:6065–73.Girard G., Robic J. Vaccination pesteuse par germs vivants (virus vaccine EV) Trois annees de l’application a Madagaskar. Bull. Acad. Med. 1938; 120:54–60.Girard G., Robic J. Vaccination pesteuse par germs vivants (virus vaccine EV) Trois annees de l’application a Madagaskar. Bull. Acad. Med. 1938; 120:54–60.Hines J., Skizypek E., Kajava A.V. Structure-function analysis of Yersinia pestis YopM’s interaction with α-thrombin to rule on its significance in systemic plague and to model YopM's mechanism of binding host proteins. Microb. Pathog. 2001; 30(4):193–209.Hines J., Skizypek E., Kajava A.V. Structure-function analysis of Yersinia pestis YopM’s interaction with α-thrombin to rule on its significance in systemic plague and to model YopM’s mechanism of binding host proteins. Microb. Pathog. 2001; 30(4):193–209.Jones A., Bosio C., Duffy A., Goodyear A., Schriefer M., Dow S. Protection against pneumonic plague following oral immunization with a non-replicating vaccine. Vaccine. 2010; 28:5924–9.Jones A., Bosio C., Duffy A., Goodyear A., Schriefer M., Dow S. Protection against pneumonic plague following oral immunization with a nonreplicating vaccine. Vaccine. 2010; 28:5924–9.Khader S., Partida-Sanchez S., Bell G., Jelley-Gibbs D., Swain S., Pearl J., Ghilardi N., Desauvage F., Lund F., Cooper A. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J. Exp. Med. 2006; 203:1805–15.Khader S., Partida-Sanchez S., Bell G., Jelley-Gibbs D., Swain S., Pearl J., Ghilardi N., Desauvage F., Lund F., Cooper A. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J. Exp. Med. 2006; 203:1805–15.Kumar D., Kirimanjeswara G., Metzger D.W. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin. Vaccine Immunol. 2010; 18(11):1925–35.Kumar D., Kirimanjeswara G., Metzger D.W. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin. Vaccine Immunol. 2010; 18(11):1925–35.Lahteemaki K., Kukkonen M., Korhonen T.K. Pia surface protease/adhesin of Yersinia pestis mediates bacterial invasion into human endothelial cells. FEMS Lett. 2001; 504(7):69–72.Lahteemaki K., Kukkonen M., Korhonen T.K. Pia surface protease/adhesin of Yersinia pestis mediates bacterial invasion into human endothelial cells. FEMS Lett. 2001; 504(7):69–72.Li B., Yang R. Interaction between Yersinia pestis and the host immune system. Infect. Immun. 2008; 76(5):1804–11.Li B., Yang R. Interaction between Yersinia pestis and the host immune system. Infect. Immun. 2008; 76(5):1804–11.Mellado-Sanchez G., Ramirez K., Drachenberg C.B., Diaz-McNair J., Rodriguez A.L., Galen J.E., Nataro J.P., Pasetti M.F. Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. Comp. Immun. Microbiol. Infect. Dis. 2013; 36:113–28.Mellado-Sanchez G., Ramirez K., Drachenberg C.B., Diaz-McNair J., Rodriguez A.L., Galen J.E., Nataro J.P., Pasetti M.F. Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. Comp. Immun. Microbiol. Infect. Dis. 2013; 36:113–28.Montminy S.W., Khan N., McGrath S., Walkowicz M.J., Sharp F., Conlon J.E., Fukase K., Kusumoto S., Sweet C., Miyake K., Akira S., Cotter R.J., Goguen J.D., Lien E. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol. 2006; 7(10):1066–73.Montminy S.W., Khan N., McGrath S., Walkowicz M.J., Sharp F., Conlon J.E., Fukase K., Kusumoto S., Sweet C., Miyake K., Akira S., Cotter R.J., Goguen J.D., Lien E. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol. 2006; 7(10):1066–73.Navarro L., Alto N.M., Dixon J.E. Functions of the Yersinia effector proteins in inhibiting host immune responses. Curr. Opin. Microbiol. 2005; 8(1):21–7.Navarro L., Alto N.M., Dixon J.E. Functions of the Yersinia effector proteins in inhibiting host immune responses. Curr. Opin. Microbiol. 2005; 8(1):21–7.Parent M.A., Berggren K.N,. Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., Smiley S.T. Cell-mediated protection againstpulmonary Yersinia pestis infection. Infect. Immun. 2005; 73:7304–10.Parent M.A., Berggren K.N,. Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., Smiley S.T. Cell-mediated protection againstpulmonary Yersinia pestis infection. Infect. Immun. 2005; 73:7304–10.Parent M.A., Wilhelm L.B., Kummer L.W., Szaba F.M., Mullarky I.K., Smiley S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect. Immun. 2006; 74:3381–6.Parent M.A., Wilhelm L.B., Kummer L.W., Szaba F.M., Mullarky I.K., Smiley S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect. Immun. 2006; 74:3381–6.Quenee L.E., Hermanas T.M., Ciletti N., Louvel H., Miller N.C., Elli D., Blaylock B., Mitchell A., Schroeder J., Krausz T., Kanabrocki J., Schneewind O. Hereditary hemochromatosis restores the virulence of plague vaccine strains. J. Infect. Dis. 2012; 7:1050–58.Quenee L.E., Hermanas T.M., Ciletti N., Louvel H., Miller N.C., Elli D., Blaylock B., Mitchell A., Schroeder J., Krausz T., Kanabrocki J., Schneewind O. Hereditary hemochromatosis restores the virulence of plague vaccine strains. J. Infect. Dis. 2012; 7:1050–58.Reisner B.S., Straley S.C. Yersinia pestis YopM: thrombin binding and overexpression. Infect. Immun. 1992; 60:5242–52.Reisner B.S., Straley S.C. Yersinia pestis YopM: thrombin binding and overexpression. Infect. Immun. 1992; 60:5242–52.Robinson W.H. Antigen arrays for antibody profiling. Curr. Opin. Chem. Biol. 2006; 10(1):67–72.Robinson W.H. Antigen arrays for antibody profiling. Curr. Opin. Chem. Biol. 2006; 10(1):67–72.Robinson R.T., Khader S.A., Locksley R.M., Lien E., Smiley S.T.,Cooper A.M. Yersinia pestis evades TLR4-dependent induction of IL-12(p40)2 by dendritic cells and subsequent cell migration. J. Immunol. 2008; 181:5560–7.Robinson R.T., Khader S.A., Locksley R.M., Lien E., Smiley S.T.,Cooper A.M. Yersinia pestis evades TLR4-dependent induction of IL-12(p40)2 by dendritic cells and subsequent cell migration. J. Immunol. 2008; 181:5560–7.Sebbane F., Jarrett C.O., Gardner D., Long D., Hinnebusch B.J. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc. Natl. Acad. Sci. USA. 2006; 103:5526–30.Sebbane F., Jarrett C.O., Gardner D., Long D., Hinnebusch B.J. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc. Natl. Acad. Sci. USA. 2006; 103:5526–30.Spinner J.L., Cundiff J.A., Kobayashi S.D. Yersinia pestis type III secretion system-dependent inhibition of human polymorphonuclear leukocyte function. Infect Immun. 2008; 76(8): 3754–60.Spinner J.L., Cundiff J.A., Kobayashi S.D. Yersinia pestis type III secretion system-dependent inhibition of human polymorphonuclear leukocyte function. Infect Immun. 2008; 76(8): 3754–60.Sun W., Roland K.L., Kuang X., Branger C.G., Curtiss R. III. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague. Infect. Immun. 2010; 78:1304–13.Sun W., Roland K.L., Kuang X., Branger C.G., Curtiss R. III. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague. Infect. Immun. 2010; 78:1304–13.Sun W., Roland K.L., Curtiss R. 3rd. Developing live vaccines against Yersinia pestis. J. Infect. Dev. Ctries. 2011; 5:614–27.Sun W., Roland K.L., Curtiss R. 3rd. Developing live vaccines against Yersinia pestis. J. Infect. Dev. Ctries. 2011; 5:614–27.Telepnev M.V., Klimpel G.R., Haithcoat J., Knirel Y.A., Anisimov A.P., Motin V.L. Tetraacylated lipopolysaccharide of Yersinia pestis can inhibit multiple Toll-like receptor-mediated signaling pathways in human dendritic cells. J. Infect. Dis. 2009; 200:1694–702.Telepnev M.V., Klimpel G.R., Haithcoat J., Knirel Y.A., Anisimov A.P., Motin V.L. Tetraacylated lipopolysaccharide of Yersinia pestis can inhibit multiple Toll-like receptor-mediated signaling pathways in human dendritic cells. J. Infect. Dis. 2009; 200:1694–702.Viboud G.I., Bliska J.B. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu Rev. Microbiol. 2005; 59:69–89.Viboud G.I., Bliska J.B. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu Rev. Microbiol. 2005; 59:69–89.Wang Z., Zhou L., Qi Z., Zhang Q., Dai R., Yang Y., Cui B., Wang H., Yang R., Wang X. Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice. Clin. Vaccine Immunol. 2010; 17(1):199–201.Wang Z., Zhou L., Qi Z., Zhang Q., Dai R., Yang Y., Cui B., Wang H., Yang R., Wang X. Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice. Clin. Vaccine Immunol. 2010; 17(1):199–201.Zauberman A., Cohen S., Mamroud E., Flashner Y., Tidhar A., Ber R., Elhanany E., Shafferman A., Velan B. Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis. Infect. Immun. 2006; 74(6):3239–50.Zauberman A., Cohen S., Mamroud E., Flashner Y., Tidhar A., Ber R., Elhanany E., Shafferman A., Velan B. Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis. Infect. Immun. 2006; 74(6):3239–50.Zauberman A., Tidhar A., Levy Y., Bar-Haim E., Halperin G., Flashner Y., Cohen S., Shafferman A., Mamroud E. Yersinia pestis Endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS ONE. 2009; 4(6):e5938.Zauberman A., Tidhar A., Levy Y., Bar-Haim E., Halperin G., Flashner Y., Cohen S., Shafferman A., Mamroud E. Yersinia pestis Endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS ONE. 2009; 4(6):e5938.Zhou D., Han Y., Yang R. Molecular and physiological insights into plague transmission, virulence and etiology. Microbes Infect. 2006; 8:273–84.Zhou D., Han Y., Yang R. Molecular and physiological insights into plague transmission, virulence and etiology. Microbes Infect. 2006; 8:273–84.Yersin A. La peste bubonigue a Hong Kong. Ann. Inst. Pasteur (Paris). 1894; 8:662–7.Yersin A. La peste bubonigue a Hong Kong. Ann. Inst. Pasteur (Paris). 1894; 8:662–7.

The authors declare that there are no conflicts of interest present.